Cubist Looks to Opioid Receptor Antagonists with Potential US$415 M Adolor Takeover
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 7 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1604 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
A month after GlaxoSmithKline sold all of its rights to Entereg® (alvimopan) back to Adolor, Cubist Pharmaceuticals has agreed to acquire Adolor for a potential consideration of US$415 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS